Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome
Phase 4
- Conditions
- Metabolic Syndrome
- Interventions
- Registration Number
- NCT02940366
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
This purpose of this study is to evaluate effect of high-dose Pitavastatin on glucose control in patients with metabolic syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Patients diagnosed as metabolic syndrome according to National cholesterol Education Program criteria
- Patients with hypercholesterolemia who required to start statin therapy
Exclusion Criteria
- overt diabetes
- acute coronary syndrome within 2 months
- acute cerebrovascular event within 2 months
- recent treatment of statin within 1month
- recent diagnosed neoplasm
- recent diagnosed liver disease
- chronic kidney disease
- patients with myopathy
- pregnant women, nursing mothers, women with possibility of pregnant
- patients being adminstered cyclosporine
- patients with genetic disease such as galactose intolerance, lactose intolerance, glucose-galactose malabsorption
- patients with treatment cyclosporin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pitavastatin 4 mg orally daily Pitavastatin 4 mg orally daily - Atorvastatin 20 mg orally daily Atorvastatin 20 mg orally daily -
- Primary Outcome Measures
Name Time Method Absolute change in HbA1c level baselina and after 24months treatment
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Pitavastatin target to improve glucose control in metabolic syndrome patients compared to Atorvastatin?
How does high-dose Pitavastatin compare to Atorvastatin in managing insulin resistance and lipid profiles in metabolic syndrome?
Which biomarkers are associated with differential response to high-dose Pitavastatin versus Atorvastatin in metabolic syndrome patients?
What are the long-term adverse event profiles of high-dose Pitavastatin and Atorvastatin in metabolic syndrome populations?
How does Pitavastatin's HMG-CoA reductase inhibition compare to other statins in preventing diabetes progression in metabolic syndrome?
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital🇰🇷Seoul, Korea, Republic ofHyung-Kwan Kim, MDPrincipal Investigator